Target-recognition of antigen-mhc complex reporter (tracer) platform
AssigneeThe Board of Trustees of the Leland Stanford Junior University
InventorsPossu Huang, Haotian Du
Life of this patent
Estimating the term…
Abstract
Abstract: Compositions and methods are provided relating to the design, screening and therapeutic use of designed binding proteins that specifically interact with an MHC/peptide complex. Proteins that specifically bind to an MHC/antigenic peptide complex of interest are designed through engineering of protein structure and screening assays. Selected binders are screened to minimize cross-reactivity with self-MHC-peptides. The antigen binding region thus developed can be formatted into a therapeutic agent that activates cytolytic pathways.
Claims19
A population of polypeptides comprising a sequence characterized as:
- at least 85% sequence identity to SEQ ID NO:1, residues 1-124;
- comprising a randomized region of from 1 to 10 amino acids within residues 12 and 22;
- comprising two cysteine residues that form a disulfide bond;
- wherein a polypeptide in the population binds to a Class II MHC protein with an affinity of less than 106M.
A population of polypeptides comprising an amino acid sequence of SEQ ID NO:2, SEQ ID NO:3, or SEQ ID NO:4, wherein a polypeptide in the population binds to a Class II MHC protein with an affinity of less than 10-6M, optionally wherein the population comprises at least 106 different sequences.
4-5. (canceled)
(canceled)
(canceled)
13-14. (canceled)
(canceled)
(canceled)
A polypeptide comprising a sequence according to any of SEQ ID NO:10, 11, 12, 13 or 16.
21-33. (canceled)
Dependencies are inferred from the claim text.